Denali Therapeutics Appoints Dana Andersen, Ph.D., as Chief Technical and Manufacturing Officer
08 August 2018 - 6:30AM
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical
company developing a broad portfolio of product candidates for
neurodegenerative diseases, today announced that Dr. Dana Andersen
has joined the company as Chief Technical and Manufacturing
Officer.
Dr. Andersen joins Denali from Genentech, where he served in
various roles for nearly 23 years, working most recently as Vice
President and Global Head of Technical Development Project &
Portfolio Management. Prior to this role, he was Vice President of
Pharmaceutical Development and held numerous leadership roles
spanning biologics manufacturing process development at
Genentech.
Dr. Andersen is a fellow of the American Institute for Medical
and Biological Engineering and received a B.S. from the University
of Colorado at Boulder, and a M.S. and Ph.D. from Stanford
University, all in chemical engineering with a focus on biological
systems.
“I am thrilled to join Denali’s team to help advance a promising
portfolio of small and large molecules addressing neurodegenerative
disease,” said Dr. Andersen.
“With our progressing portfolio, including our ATV and ETV
platforms that are designed to deliver large molecules across the
blood-brain barrier, we are pleased to welcome Dana to Denali. Dana
brings a wealth of experience in technical development of both
large and small molecule manufacturing, as well as deep leadership
experience. Dana will further build and scale our internal
manufacturing organization and lead our external technical and
manufacturing collaborations,” said Ryan Watts, Ph.D., CEO.
About Denali
Denali is a biopharmaceutical company developing a broad
portfolio of product candidates for neurodegenerative
diseases. Denali pursues new treatments by rigorously
assessing genetically validated targets, engineering delivery
across the blood-brain barrier and guiding development with
biomarker monitoring to demonstrate target engagement and
select patients. Denali is based in South San Francisco. For
additional information, please
visit www.denalitherapeutics.com.
Contacts:
Morgan Warners(202)
337-0808mwarners@gpg.com
OR
Lizzie Hyland(646)
495-2706lhyland@gpg.com
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jul 2023 to Jul 2024